10:48 AM EST - XPhyto Therapeutics Corp. : Announced an update on its transdermal delivery system ("TDS") for the neurologic drug Rotigotine. Further to the Company's press release dated, June 8, 2020, regarding formula finalization, Vektor Pharma TF GmbH ("Vektor"), a wholly owned German subsidiary of XPhyto, has now completed process implementation for the manufacture of its Rotigotine patches. With process implementation complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human bioavailability studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020. Updates to the Rotigotine drug delivery program will be provided periodically as it proceeds. XPhyto Therapeutics Corp.
shares C.XPHY are trading up 3 cents at $3.03.
